Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

121. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease.

Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. IMPORTANCE: Patients with chronic kidney disease (CKD) are at an increased risk of cardiovascular disease (CVD) compared with the general population. Prior studies have produced contradictory results on the association of dietary sodium intake with risk of CVD, and this relationship has not been investigated in patients with CKD. OBJECTIVE: To evaluate the association between urinary sodium (...) excretion and clinical CVD events among patients with CKD. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study of patients with CKD from 7 locations in the United States enrolled in the Chronic Renal Insufficiency Cohort Study and followed up from May 2003 to March 2013. EXPOSURES: The cumulative mean of urinary sodium excretion from three 24-hour urinary measurements and calibrated to sex-specific mean 24-hour urinary creatinine excretion. MAIN OUTCOMES AND MEASURES: A composite of CVD events

JAMA2016 Full Text: Link to full Text with Trip Pro

122. Role of Bile Acid Regulated Nuclear Receptor FXR and G Protein Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease)

Role of Bile Acid Regulated Nuclear Receptor FXR and G Protein Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease) 27045028 2018 01 16 2018 12 02 1524-4563 67 6 2016 06 Hypertension (Dallas, Tex. : 1979) Hypertension Role of Bile Acid-Regulated Nuclear Receptor FXR and G Protein-Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease). 1080-4 10.1161/HYPERTENSIONAHA.115.06417 Levi (...) Moshe M From the Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado AMC, Aurora. Moshe.Levi@ucdenver.edu. eng R01 AG026529 AG NIA NIH HHS United States R01 AG049493 AG NIA NIH HHS United States R01 DK098336 DK NIDDK NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review 2016 04 04 United States Hypertension 7906255 0194-911X 0 GPBAR1 protein, human 0 Receptors

Hypertension (Dallas, Tex. : 1979)2016 Full Text: Link to full Text with Trip Pro

123. Acute kidney injury and chronic kidney disease: from the laboratory to the clinic

Acute kidney injury and chronic kidney disease: from the laboratory to the clinic 26972097 2018 01 12 2018 11 13 1872-9177 12 Suppl 1 2016 Apr Nephrologie & therapeutique Nephrol. Ther. Acute kidney injury and chronic kidney disease: From the laboratory to the clinic. S41-8 10.1016/j.nephro.2016.02.005 S1769-7255(16)00036-5 Chronic kidney disease and acute kidney injury have traditionally been considered as separate entities with different etiologies. This view has changed in recent years (...) , with chronic kidney disease recognized as a major risk factor for the development of new acute kidney injury, and acute kidney injury now accepted to lead to de novo or accelerated chronic and end stage kidney diseases. Patients with existing chronic kidney disease appear to be less able to mount a complete 'adaptive' repair after acute insults, and instead repair maladaptively, with accelerated fibrosis and rates of renal functional decline. This article reviews the epidemiological studies in man

Nephrologie & therapeutique2016 Full Text: Link to full Text with Trip Pro

124. Soluble Urokinase Receptor and Chronic Kidney Disease.

Soluble Urokinase Receptor and Chronic Kidney Disease. Soluble Urokinase Receptor and Chronic Kidney Disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26962914 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Mar 3;374(9):891. doi: 10.1056/NEJMc1515787. Soluble Urokinase Receptor and Chronic Kidney Disease. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2015] PMID: 26962914 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substance Full Text Sources Medical PubMed Commons 0 comments

NEJM2016 Full Text: Link to full Text with Trip Pro

125. Soluble Urokinase Receptor and Chronic Kidney Disease.

Soluble Urokinase Receptor and Chronic Kidney Disease. Soluble Urokinase Receptor and Chronic Kidney Disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26962915 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Mar 3;374(9):890. doi: 10.1056/NEJMc1515787#SA1. Soluble Urokinase Receptor and Chronic Kidney Disease. 1 , 1 , 1 . 1 University of Piemonte Orientale, Novara, Italy claudio.musetti@med.uniupo.it. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2015] PMID: 26962915 DOI: [Indexed for MEDLINE] Publication types MeSH

NEJM2016 Full Text: Link to full Text with Trip Pro

126. Soluble Urokinase Receptor and Chronic Kidney Disease.

Soluble Urokinase Receptor and Chronic Kidney Disease. Soluble Urokinase Receptor and Chronic Kidney Disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26962916 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Mar 3;374(9):890. doi: 10.1056/NEJMc1515787#SA2. Soluble Urokinase Receptor and Chronic Kidney Disease. 1 , 2 , 3 . 1 University of Freiburg Medical Center, Freiburg, Germany ms@imbi.uni-freiburg.de. 2 Würzburg University Clinic, Würzburg, Germany. 3 University of Ulm, Ulm, Germany. Comment in [N Engl J Med. 2016] Comment

NEJM2016 Full Text: Link to full Text with Trip Pro

127. Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study.

Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study. BACKGROUND: The risk for chronic kidney disease (CKD) among obese persons without obesity-related metabolic abnormalities, called metabolically healthy obesity, is largely unexplored. OBJECTIVE: To investigate the risk for incident CKD across categories of body mass index in a large cohort of metabolically healthy men and women. DESIGN: Prospective cohort study. SETTING: Kangbuk Samsung Health Study (...) . These associations were consistently seen in all clinically relevant subgroups. LIMITATION: Chronic kidney disease was identified by a single measurement at each visit. CONCLUSION: Overweight and obesity are associated with an increased incidence of CKD in metabolically healthy young and middle-aged participants. These findings show that metabolically healthy obesity is not a harmless condition and that the obese phenotype, regardless of metabolic abnormalities, can adversely affect renal function. PRIMARY

Annals of Internal Medicine2016

128. Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease

Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease 27733948 2018 11 13 2147-9720 3 3 2016 Sep European journal of rheumatology Eur J Rheumatol Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease. 144-145 Oiwa Hiroshi H Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. Mokuda Sho S (...) Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Department of Immunology, Hiroshima University School of Biomedical and Health, Hiroshima, Japan. eng Journal Article 2016 01 29 Turkey Eur J Rheumatol 101656068 2147-9720 Dr. Oiwa reports personal fees from Daiichi Sankyo, during the conduct of the study. 2015 07 02 2015 08 01 2016 10 14 6 0 2016 10 14 6 0 2016 10 14 6 1 ppublish 27733948 10.5152/eurjrheum.2015.0049 ejr-3-3-144 PMC5058456 Am J Kidney Dis. 2009 Jun

European journal of rheumatology2016 Full Text: Link to full Text with Trip Pro

129. The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1

The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1 28197495 2018 11 13 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1. 24-25 Einollahi Behzad B Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Lotfiazar Aidin A Nephrology and Urology (...) Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. eng Journal Article 2016 01 12 Iran J Nephropharmacol 101679372 2345-4202 Autosomal dominant polycystic kidney disease Chronic kidney disease Endothelin-1 2015 12 27 2016 01 10 2017 2 16 6 0 2017 2 16 6 0 2017 2 16 6 1 epublish 28197495 PMC5297502 Am J Kidney Dis. 1990 Nov;16(5):403-13 2239929 Iran J Kidney Dis. 2014 Jul;8(4):265-77 25001132 Lancet. 2007 Apr 14;369(9569):1287-301 17434405 J Am Soc Nephrol. 2013 May;24(6):1006

Journal of nephropharmacology2016 Full Text: Link to full Text with Trip Pro

130. ERBP Guideline on Management of Older Patients with Chronic Kidney Disease

ERBP Guideline on Management of Older Patients with Chronic Kidney Disease Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m2) | Nephrology Dialysis Transplantation | Oxford Academic We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Account Menu Menu Navbar Search Filter Mobile (...) Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation November 2016 Article Contents Article Navigation Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m 2 ) Ken Farrington Search for other works by this author on: Adrian Covic Search for other works by this author on: Fillipo Aucella Search for other works by this author on: Naomi Clyne Search for other

European Renal Best Practice2016

131. Decision Support for Adults Living with Chronic Kidney Disease

Decision Support for Adults Living with Chronic Kidney Disease Decision Support for Adults Living with Chronic Kidney Disease | Registered Nurses' Association of Ontario l’Association des infirmières et infirmiers autorisés de l’Ontario Speaking out for nursing. Speaking out for health. » » Decision Support for Adults Living with Chronic Kidney Disease Type of Guideline: Clinical Status: Published Publish Date: 2009 About this Guideline : The purpose of this best practice guideline is: To help (...) nurses recognize patients with CKD experiencing decisional conflict related to situations in which there is more than one option available for managing their condition. To help nurses support patient involvement in reaching quality health decisions. Quality decisions are made using the best available evidence about the options and are consistent with the patients’ values. Clinical questions addressed in the guideline include: What are the common health decisions faced by patients with CKD? How can

Registered Nurses' Association of Ontario2016

132. Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes

Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has

Evidence-Based Medicine (Requires free registration)2016

133. What Is the Significance of Elevated Troponin in Patients With Suspected Acute Coronary Syndrome and Chronic Kidney Disease?

What Is the Significance of Elevated Troponin in Patients With Suspected Acute Coronary Syndrome and Chronic Kidney Disease? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2016

134. Chronic kidney disease - not diabetic

Chronic kidney disease - not diabetic Chronic kidney disease - not diabetic - NICE CKS Clinical Knowledge Summaries Share Chronic kidney disease - not diabetic - Summary Chronic kidney disease (CKD) is an abnormality of kidney function or structure that is present for more than 3 months, with implications for health. Complications of CKD include worsening renal disease that progresses to renal replacement therapy, cardiovascular disease, renal anaemia, renal bone disease, malnutrition (...) hypertension. Suspected renal artery stenosis. A rare genetic cause of CKD. Complications such as anaemia or renal bone disease. Have I got the right topic? Age from 18 years onwards This CKS topic is based on the National Institute for Health and Care Excellence (NICE) guideline, Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care [ ]. This CKS topic covers the identification and management of chronic kidney disease in adults

NICE Clinical Knowledge Summaries2016

135. Growth Monitoring for Children with Chronic Kidney Disease

Growth Monitoring for Children with Chronic Kidney Disease S Trace, E Cameron, C Inward, CP Burren, Jul 2016 Review date Jul 2018 Page 1 of 5 Bristol Royal Hospital for Children Growth Monitoring Guideline for Children with CKD Contents Page 1-2 Scope, Background, Rationale and Evidence base for guideline Page 2 Definition of Stages of Chronic Kidney Disease (CKD) Page 3 Notes on Growth Monitoring and Referral Page 4 Growth Monitoring Timetable Page 5 References The guideline scope extends (...) -moderate chronic renal insufficiency 2,4 . Short stature is associated with increased morbidity and mortality 5,6 . A combination of regular anthropometric measurements, clinical assessment of growth and a nutritional assessment is an essential part of treatment in these children 7,8 . The guideline rationale is that growth is documented in a proportion of those receiving renal replacement therapy (published in the UK Renal Registry report), leaving scope for improved monitoring for identification

British Society for Paediatric Endocrinology and Diabetes2016

136. Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes

Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes 28197489 2018 11 13 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes. 4-6 Assari Shervin S Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA ; Center for Research (...) on Ethnicity, Culture and Health, School of Public Health, University of Michigan, Ann Arbor, MI, USA. eng R01 AG018418 AG NIA NIH HHS United States Editorial 2015 12 12 Iran J Nephropharmacol 101679372 2345-4202 Chronic kidney disease End stage renal disease Health disparities Socio-economics 2015 10 07 2015 12 05 2017 2 16 6 0 2015 12 12 0 0 2015 12 12 0 1 epublish 28197489 PMC5297505 Am J Mens Health. 2013 Jul;7(4 Suppl):58S-67S 23609347 J Diabetes Complications. 2003 Jan-Feb;17(1):39-58 12505756 Clin J

Journal of nephropharmacology2015 Full Text: Link to full Text with Trip Pro

137. Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients

Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients 28197493 2018 11 13 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients. 13-18 Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the presence of numerous cysts (...) in the kidney and manifest with various renal and extra-renal complications leading to ESRD. Endothelin may contribute to various renal and extra-renal manifestations pointing to genetic and environmental modifying factors that alter the risk of developing chronic kidney disease (CKD) in ADPKD. In the present study we investigated six genes coding for endothelin 1 ( EDN1 ) tagging-single nucleotide polymorphisms (tag-SNPs) to unravel the EDN1 gene modifier effect for renal disease progression in ADPKD

Journal of nephropharmacology2015 Full Text: Link to full Text with Trip Pro

138. Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD)

Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD) Sonidegib (Odomzo ® ) capsule Novartis Pharmaceuticals UK Ltd November 2015 Advice context: The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Care Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication

All Wales Medicines Strategy Group2015

139. A suPAR Biomarker for Chronic Kidney Disease.

A suPAR Biomarker for Chronic Kidney Disease. A suPAR Biomarker for Chronic Kidney Disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26539740 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Nov 12;373(20):1971-2. doi: 10.1056/NEJMe1512997. Epub 2015 Nov 5. A suPAR Biomarker for Chronic Kidney Disease. 1 , . 1 From the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Rambam Health Care Campus, Haifa, Israel (K.L.S.); and the Department of Internal Medicine, Section on Nephrology, Wake Forest School

NEJM2015

140. Soluble Urokinase Receptor and Chronic Kidney Disease.

Soluble Urokinase Receptor and Chronic Kidney Disease. BACKGROUND: Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease (...) . METHODS: We measured plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear

NEJM2015 Full Text: Link to full Text with Trip Pro